Recent Updates
Recently added Catalysts
GNLX Positive Sentiment

Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023

Wednesday, August 2, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Genelux Corporation announced that its President and CEO, Thomas Zindrick, will participate in a fireside chat at BTIG's Virtual Biotechnology Conference on August 8, 2023. The discussion will cover the company's clinical-stage programs, recent announcements, and future milestones. This event may provide valuable insights into Genelux's progress and developments in immuno-oncology.
Price reaction · baseline $20.5 (2023-08-01 close) · hit after-hours · clean, no other GNLX news in the window
day 0 close
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Genelux Corporation will showcase its clinical-stage programs.
  • Participation in a prominent conference indicates growing visibility.
  • The event will include discussions on recent announcements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~8 mo
Medium dilution risk
Lead asset
olvimulogene nanivacirepvec
Phase 3 · Platinum-resistant Ovarian Cancer

Full Press Release Details

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.
The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 4:00 p.m. ET on Tuesday, August 8, 2023.
About Genelux Corporation
Investor and Media Contacts
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation

Frequently Asked Questions

What will Genelux discuss at the BTIG Virtual Conference?

Genelux will review clinical-stage programs, recent announcements, and milestones.

When is the Genelux fireside chat scheduled?

The chat is set for August 8, 2023, at 4:00 p.m. ET.

Who will lead the discussion with Genelux's CEO?

Kaveri Pohlman, PhD, will moderate the conversation.

What is Genelux Corporation focused on?

Genelux is a late clinical-stage immuno-oncology company.

Who can be contacted for media inquiries about Genelux?

Media inquiries can be directed to Allele Communications, LLC.

ShareAdd on Google
Tags: GNLX Viatris Investor Conferences Healthcare Genelux Corporation immuno-oncology BTIG conference clinical-stage programs August 2023
Last updated: Aug 2, 2023

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~8 mo
Medium dilution risk
Lead asset
olvimulogene nanivacirepvecPhase 3
Platinum-resistant Ovarian Cancer →